continuous pharmaceutical manufacturing: cgmp, process ...process of capable of consistently...
TRANSCRIPT
![Page 1: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/1.jpg)
Continuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional
Considerations for Implementation
Christina Capacci-Daniel, Ph.D.Consumer Safety Officer / Acting Quality Assessment Lead
Division of Inspectional Assessment, Office of Process and FacilitiesOffice of Pharmaceutical Quality, CDER
IFPAC, San Juan – June 2016
![Page 2: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/2.jpg)
Outline• Continuous manufacturing in the Regulatory and
CGMPs framework• CGMP considerations
– Quality Unit – Equipment & computer systems
• Process Validation Approach– Assessing process robustness
![Page 3: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/3.jpg)
FDA View of Continuous Pharmaceutical Processing
• FDA supports continuous processing for pharmaceutical manufacturing– Offers potential advantages in both development and manufacturing
• Continuous manufacturing is consistent with FDA Quality Initiatives– More modern manufacturing approach– Potential to improve assurance of quality and consistency of drugs– Enables quality to be directly built into process design
3
![Page 4: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/4.jpg)
CGMPs & Continuous Manufacturing
4
The Commissioner is keenly aware that the general CGMP regulations must apply to a wide variety of drug products. Therefore, the CGMP regulations in Part 211 are intended to be:• general enough to be suitable for essentially all drug
products,• flexible enough to allow the use of sound judgment and
permit innovation, and • explicit enough to provide a clear understanding of what is
required. Preamble to 21 CFR 210 & 211, March 1979
![Page 5: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/5.jpg)
CGMPs & Continuous Manufacturing
• CGMP’s are intended to be flexible and amendable to new technology– Production and Process Controls – Equipment, Laboratory Controls, Records
• In implementing CM, the Quality Assurance Unit may appear to have the greatest challenges adapting.– Compressed timeframes– Immediate decision-making on in-process and finished materials– New ways of thinking about old business processes
5
![Page 6: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/6.jpg)
Responsibilities of the QC Unit• 21 CFR 211.22 – “The Quality Control Unit shall have the responsibility
and authority to”… approve and reject all incoming components, in-process materials, and final product.
• Materials are isolated and individually approved• Hold time studies allow for investigation periods if needed
6
![Page 7: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/7.jpg)
Responsibilities of the QC Unit• 21 CFR 211.22 – “The Quality Control Unit shall have the responsibility
and authority to”… approve and reject all incoming components, in-process materials, and final product.
• Material is constantly generated and moved forward• Rapid transmission of material requires an adequate control strategy and
significant process development• But most importantly, QC oversight must be built into process
decision-making.7
![Page 8: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/8.jpg)
QCU and Automation• CM equipment is highly reliant on automation software for control and
monitoring• Quality decision making must be programed into the automation:
– Interlocks, communication checks, recipe integrity, data collection frequency– Monitoring , Alert & alarm limits, segregation points, automatic stops– Start up sequence, restart, material collection criteria, and shut-down
processes• Some oversight is delegated to the automation but the QCU is ultimately
responsible for the product
8
QCUQCU
And…..
Wikimedia Commons
![Page 9: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/9.jpg)
Importance of Automation Validation• 21 CFR 211.63 – Equipment must be suitable for intended
use.
• User requirements include both technical and quality functionality.
• Installation / Operational / Performance Qualification should consider both unit component functionality as well as the entirety of the integrated system.
• OQ/PQ should consider the relative risk and impact to product of the automation design specifications
9
![Page 10: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/10.jpg)
Maintenance of Automation• 21 CFR 211.67 – Equipment shall be maintained as
appropriate according to procedures to prevent malfunction that would alter the drug product.
• Robust change control process for code improvements– Design, testing, implementation, & confirmation
• Monitoring of automation performance– QCU should be auditing the “delegated” responsibilities
• Version control, back-ups, and security
10
![Page 11: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/11.jpg)
Deviation Preparation• 21 CFR 211.22 & 192 – Failure to meet any specification
shall be thoroughly investigated.
• Proactive QCU• Deep understanding of process is required
– Have identified potential failure modes– Detectability: process parameters & PAT signals– Clear plan of action justified and determined in advance– Overall batch quality: What is acceptable control?
• This decision-making also feeds into Quality Control Strategy and automation
11
![Page 12: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/12.jpg)
• Monitoring of process parameters & PAT measurement of attributes
• State of control vs. flux and impact on material collection
Control and Process Risk
12
Accept
Reject
Upper Limit
Lower Limit
Target
![Page 13: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/13.jpg)
Control and Process Risk• Risk to Product
– Detect and remove OOS or potentially OOS material
• Risk to Process– Maintaining a state of control, establish thresholds for “in control”– Does limited control over the entire batch manufacturing period pose
an indirect threat to product quality?
• Batch review– Percent yield and state of control– Time in control, frequency of rejection
• Examine process and variability through robust Process Validation
13
![Page 14: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/14.jpg)
Process Validation• Process Validation – The collection and evaluation of data,
from the process design stage through commercial production, which establishes scientific evidence that a process of capable of consistently delivering quality products.
• Process Qualification – Confirming that the manufacturing process as designed is capable of reproducible commercial manufacturing.
14
FDA Guidance for Industry, Process Validation: General Principles and Practices, Revision 1, January 2011.
![Page 15: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/15.jpg)
Process Validation - Stage 1• Process Design
– Equipment– Material inputs and attributes– RTD Studies, system dynamics
• Control Strategy– Parameter monitoring and acceptable ranges– PAT points, sampling rates, models
15
![Page 16: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/16.jpg)
Process Validation - Stage 2a• Qualification of equipment and automation• Operates in accordance with the process
requirements over the entire anticipated operating range– Expected conditions, stresses, duration
16
![Page 17: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/17.jpg)
Process Validation - Stage 2b• Understand the Process Design• Material Attributes established• Process Parameters set• PAT points and models• Facilities and Equipment have been adequately qualified
• Confirm process design and control strategy for the intended scale of manufacturing
• Demonstrate capability to reproducibly manufacture commercial product
17
![Page 18: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/18.jpg)
Process Performance Qualification• Seeks to confirm effectiveness of control strategy• Evaluate adequate performance of process with expected
variability of inputs and process to confirm robustness• For CM especially, demonstrate that the process can achieve
and maintain a state of control• Pre-determined in PPQ Protocol
– Length of CM run and number of batches– Attributes to be monitored– Acceptance criteria: for each attribute and for the batch– Definition of a “successful” batch
18
![Page 19: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/19.jpg)
Assessing Robustness• Unlike batch processes, the quantity of material produced by
CM is directly related to the amount of time operating in a state of control
• To assess robustness during PPQ, there should be some expectation for yield in a CM process
• But….. may not be as simple as percent yield– Number of diversion vs. time of each diversion– Start up losses and inherent waste
• Definition of “yield” must be very clear• Measure of PPQ “success” must be determined in advance
19
![Page 20: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/20.jpg)
PPQ Protocol• Should include typical operations
– Start up, pauses, & restarts if part of the process– Run length– Expected interventions
• PAT probe cleaning or replacement, refill events
• Sources of variability– Incoming materials– Equipment fatigue
20
![Page 21: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/21.jpg)
Continued Process Verification• Establish a program to collect and analyze product
and process data related to product quality– Establish Monitoring plan– Frequency of trending and analysis– Attributes
• Understanding of remaining variability• Detect abnormalities• Statistical approach highly recommended
21
![Page 22: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/22.jpg)
Summary• Continuous Manufacturing is highly compatible with
CGMPs– Quality oversight is a universal expectation– Suitability and performance of physical and electronic
equipment• Thorough Process Validation enhances the
robustness of processes designed and intended to remain in a constant state of control
22
![Page 23: Continuous Pharmaceutical Manufacturing: CGMP, Process ...process of capable of consistently delivering quality products. • Process Qualification – Confirming that the manufacturing](https://reader030.vdocument.in/reader030/viewer/2022041015/5ec5e15e8314ca5b1e4e0f8a/html5/thumbnails/23.jpg)
Acknowledgements• Mahesh Ramanadham, PharmD• Dave Doleski• Rapti Madurawe, PhD• Sharmista Chatterjee, PhD
23